|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
Why Biogen Idec Got Out of the Corporate VC Business
|
Luke Timmerman |
01/27/12 |
Boston
|
|
New England’s Rising Biotech CEOs to Gather at April 4 Xconomy Event
|
Arlene Weintraub |
01/26/12 |
Boston
|
|
San Diego Life Sciences Roundup: Isis, Elevation, Proacta, and More
|
Bruce V. Bigelow |
01/06/12 |
San Diego
|
|
Alnylam, Aveo, Biogen, & More Boston Life Sciences Newsmakers
|
Erin Kutz |
01/06/12 |
Boston
|
|
Isis, Biogen Strike Potential $299M Deal For Rare Spine Disorder Treatment
|
Luke Timmerman |
01/04/12 |
San Diego
|
|
Editor’s Picks: Xconomy Boston’s Top 20ish Stories of 2011
|
Gregory T. Huang |
12/28/11 |
Boston
|
|
Allozyne Raises More VC Cash, Looks to FDA Meeting After Poniard Deal Fizzles
|
Luke Timmerman |
12/23/11 |
Seattle
|
|
Momenta, Baxter Team Up on Biosimilars
|
Erin Kutz |
12/23/11 |
Boston
|
|
Boston’s Women in Bio Aims to Fuel STEM Curiosity In Middle Schoolers
|
Amy Speak |
12/23/11 |
Boston
|
|
EnVivo, Biogen, Momenta, & Other Boston-Area Life Sciences Newsmakers
|
Erin Kutz |
12/09/11 |
Boston
|
|
The Genetics Institute Impact: Agenda for Xconomy’s Big Event Dec. 14
|
Luke Timmerman |
12/08/11 |
Boston
|
|
Biogen Idec Boosts Biogenerics Strategy With $300M Samsung Joint Venture
|
Arlene Weintraub |
12/06/11 |
Boston
|
|
Seattle Genetics Sees Case of PML, Causing Market Twitch
|
Luke Timmerman |
12/01/11 |
Seattle
|
|
Today’s Xconomy Report: Biogen Idec Meets Goals in Clinical Trial, iRobot Layoffs, $1M Awarded by MassChallenge, and Bay State Venture Capital Earnings
|
Lilly O'Flaherty |
10/28/11 |
Boston
|
|
Editor’s Picks: Xconomy Boston’s Top 20 Stories of the Third Quarter
|
Gregory T. Huang |
10/28/11 |
Boston
|
|
New Genzyme CEO, Biogen Scores in 2nd MS Pill Trial, Nanotech Drug Startups Nab Funds, & More Boston-Area Life Sciences News
|
Erin Kutz |
10/28/11 |
Boston
|
|
Portola Grabs $45M Upfront From Biogen Idec to Develop Autoimmune Drugs
|
Luke Timmerman |
10/27/11 |
San Francisco
|
|
Biogen Idec’s Oral Multiple Sclerosis Drug Passes 2nd Major Test; Stock Soars
|
Luke Timmerman |
10/26/11 |
Boston
|
|
Sha Mi, Biogen Idec’s Neurology Ace, to Join “The Genetics Institute Impact” on Dec. 14
|
Luke Timmerman |
10/21/11 |
Boston
|
|
Fearless Fantasy Football, Uh, I Mean Biotech, Predictions for the Season Ahead
|
Luke Timmerman |
09/06/11 |
National
|
|
Pfizer Grows in Cambridge, Repligen Eyes Imaging Approval, GI Dynamics Gets Aussie IPO, & More Boston-Area Life Sciences News
|
Erin Kutz |
09/02/11 |
Boston
|
|
George Scangos, the Boy From Working Class Boston, on His Road Back to Lead Biogen Idec
|
Luke Timmerman |
08/31/11 |
Boston
|
|
Verizon Buys CloudSwitch, Adimab Inks Biogen and Novo Nordisk Deals, EMD Millpore Buys Amnis, & More Boston-Area Deals News
|
Erin Kutz |
08/31/11 |
Boston
|
|
Adimab Inks Collaboration Deals with Biogen Idec, Novo Nordisk
|
Erin Kutz |
08/29/11 |
Boston
|
|
Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies
|
Luke Timmerman |
08/29/11 |
Seattle
|
|
Verizon’s Software Beachhead in Boston: The Story Behind CloudSwitch and Terremark
|
Gregory T. Huang |
08/26/11 |
Boston
|
|
Biogen Gets Euro Approval, BSX Shows Solid Q2, Alkermes Tries Again, & More Boston-Area Life Sciences News
|
Erin Kutz |
07/29/11 |
Boston
|
|
Biogen Confirms Cambridge Move, Amag Merges With Allos, ACT Kicks Off Trials, & More Boston-Area Life Sciences News
|
Erin Kutz |
07/22/11 |
Boston
|
|
Biogen Idec Moving HQ Back to Cambridge, Constructing Two New Buildings at Kendall Square
|
Luke Timmerman |
07/20/11 |
Boston
|
|
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent
|
Luke Timmerman |
07/18/11 |
National
|
|
Page 1 of
14 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.